down arrow

GE Healthcare Technologies, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36266G1076
USD
82.52
2.3 (2.87%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

81.5583.70

52 Week

57.6594.80
Valuation
Technical
Day's Volume

CASH

3.32 M

Shareholding (Mar 2025)

FII

16.10%

Held by 407 FIIs

DII

36.5%

Held by 91 DIIs

Promoter

2.95%

How big is GE Healthcare Technologies, Inc.?

22-Jun-2025

As of Jun 18, GE Healthcare Technologies, Inc. has a market capitalization of $32.57 billion, with net sales of $19.80 billion and a net profit of $2.25 billion over the latest four quarters. The company reports shareholder's funds of $8.45 billion and total assets of $33.09 billion.

As of Jun 18, GE Healthcare Technologies, Inc. has a market capitalization of 32,573.94 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the company reported net sales of 19,798.00 million for the latest four quarters, alongside a net profit of 2,251.00 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 8,447.00 million and total assets amounting to 33,089.00 million.

Read More

What does GE Healthcare Technologies, Inc. do?

22-Jun-2025

GE Healthcare Technologies, Inc. is a large-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $4.777 billion and a net profit of $588 million. It has a market cap of approximately $32.57 billion, a P/E ratio of 14.00, and a return on equity of 25.79%.

Overview:<BR>GE Healthcare Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,777 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 588 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 32,573.94 Million <BR><BR>Key Metrics:<BR>P/E: 14.00 <BR>Debt Equity: 0.70 <BR>Return on Equity: 25.79% <BR>Price to Book: 3.55 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is GE Healthcare Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, GE Healthcare Technologies, Inc. shows a mildly bearish trend with underperformance against the S&P 500, indicated by bearish moving averages and mixed MACD signals.

As of 12 September 2025, the technical trend for GE Healthcare Technologies, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The daily moving averages are bearish, and the KST is bearish on a weekly basis. Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. <BR><BR>In terms of returns, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.35% versus the S&P 500's 12.22%, and a one-year return of -16.41% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the bearish moving averages and mixed signals from MACD and Bollinger Bands.

Read More

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

18-Nov-2025

As of November 14, 2025, GE Healthcare Technologies, Inc. is considered fairly valued with a P/E ratio of 14, making it more attractive compared to peers like Edwards Lifesciences and Agilent Technologies, despite a year-to-date return of -9.66% compared to the S&P 500's 14.49%.

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential.<BR><BR>In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 18.55%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.11 times

 
3

Flat results in Jun 25

4

With ROCE of 18.89%, it has a attractive valuation with a 2.51 Enterprise value to Capital Employed

5

High Institutional Holdings at 93.07%

6

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 35,685 Million (Mid Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.68

stock-summary
Return on Equity

24.38%

stock-summary
Price to Book

3.67

Revenue and Profits:
Net Sales:
5,007 Million
(Quarterly Results - Jun 2025)
Net Profit:
500 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.01%
0%
14.01%
6 Months
15.96%
0%
15.96%
1 Year
-0.06%
0%
-0.06%
2 Years
18.89%
0%
18.89%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

GE Healthcare Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential. In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector....

Read More

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its current metrics, particularly when compared to its peers. The P/E ratio stands at 14, while the PEG ratio is notably low at 0.39, suggesting that the stock is priced attractively relative to its growth potential, but this is offset by a relatively high Price to Book Value of 3.57. In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than that of Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating that it may be undervalued relative to these companies. However, the overall market performance shows that GE Healthcare has underperformed the S&P 500 year-to-date with a return of -6.43% compared to the index's 14.49%, reinforcin...

Read More

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, suggesting that the stock is reasonably priced relative to its growth prospects. In comparison to its peers, GE Healthcare Technologies has a lower P/E ratio than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating it may be undervalued relative to these companies. The company's recent performance shows a year-to-date return of -6.43%, while the S&P 500 has returned 14.49%, reinforcing the notion that the stock may be underperforming the broader market....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.41%
EBIT Growth (5y)
6.92%
EBIT to Interest (avg)
7.73
Debt to EBITDA (avg)
2.11
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
1.10
Tax Ratio
18.50%
Dividend Payout Ratio
2.88%
Pledged Shares
0
Institutional Holding
93.07%
ROCE (avg)
18.55%
ROE (avg)
26.44%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
3.57
EV to EBIT
13.31
EV to EBITDA
11.16
EV to Capital Employed
2.51
EV to Sales
1.98
PEG Ratio
0.39
Dividend Yield
NA
ROCE (Latest)
18.89%
ROE (Latest)
25.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 139 Schemes (44.43%)

Foreign Institutions

Held by 407 Foreign Institutions (16.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 3.47% vs 0.46% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.94% vs 0.46% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,007.00",
          "val2": "4,839.00",
          "chgp": "3.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "774.00",
          "val2": "814.00",
          "chgp": "-4.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "120.00",
          "val2": "135.00",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "28.00",
          "val2": "-58.00",
          "chgp": "148.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "500.00",
          "val2": "435.00",
          "chgp": "14.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "125.20%",
          "val2": "137.20%",
          "chgp": "-1.20%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.61% vs 6.60% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 26.70% vs -16.98% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19,672.00",
          "val2": "19,552.00",
          "chgp": "0.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,536.00",
          "val2": "3,398.00",
          "chgp": "4.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "520.00",
          "val2": "578.00",
          "chgp": "-10.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-310.00",
          "val2": "-297.00",
          "chgp": "-4.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,050.00",
          "val2": "1,618.00",
          "chgp": "26.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "150.30%",
          "val2": "142.60%",
          "chgp": "0.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
5,007.00
4,839.00
3.47%
Operating Profit (PBDIT) excl Other Income
774.00
814.00
-4.91%
Interest
120.00
135.00
-11.11%
Exceptional Items
28.00
-58.00
148.28%
Consolidate Net Profit
500.00
435.00
14.94%
Operating Profit Margin (Excl OI)
125.20%
137.20%
-1.20%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 3.47% vs 0.46% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 14.94% vs 0.46% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
19,672.00
19,552.00
0.61%
Operating Profit (PBDIT) excl Other Income
3,536.00
3,398.00
4.06%
Interest
520.00
578.00
-10.03%
Exceptional Items
-310.00
-297.00
-4.38%
Consolidate Net Profit
2,050.00
1,618.00
26.70%
Operating Profit Margin (Excl OI)
150.30%
142.60%
0.77%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.61% vs 6.60% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 26.70% vs -16.98% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About GE Healthcare Technologies, Inc. stock-summary
stock-summary
GE Healthcare Technologies, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."